IAM
VERA icon

Innovis Asset Management’s Vera Therapeutics VERA Stock Holding History

Innovis Asset Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,673
Closed -$348K – 180
2023
Q2 		$348K Buy
+21,673
New +$196K 0.13% 101

Other funds holding VERA

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Innovis Asset Management's VERA Position: Q3 2023 in Review

Innovis Asset Management sold out of Vera Therapeutics (VERA) in Q3 2023, closing a stake of 21,673 shares — an estimated $348K sold.

Innovis Asset Management first reported a position in VERA in Q2 2023 and held it in 1 quarter. The position peaked at $348K in Q2 2023. 84 funds tracked by Wall St. Rank hold VERA as of Q3 2023.

  • Innovis Asset Management reported no remaining Vera Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Innovis Asset Management sold 21,673 Vera Therapeutics shares in Q3 2023, an estimated $348K.
  • Innovis Asset Management first reported a position in Vera Therapeutics in Q2 2023 and held it in 1 quarter.
  • Innovis Asset Management's Vera Therapeutics position peaked at $348K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.